+ and CD8 + lymphocytes are at high risk of VZV infection. These patients should be considered as candidates for preventive therapy, but whether for antiviral therapy or vaccination remains to be investigated.
Varicella-zoster virus (VZV), a member of the herpesvirus family, is reported to cause severe infections, particularly in patients with hematologic malignancies who are undergoing stem cell transplantation [1, 2] or patients receiving nucleoside analogues [3] . VZV infections occur with a frequency of 16.6%-50% in allogeneic [1, 2, [4] [5] [6] and of ∼25% in autologous bone marrow transplant (BMT) recipients [7, 8] . VZV infection occurs within the first year after transplantation in 180% of the patients who develop it [2, 7] ; moreover, among patients who undergo allogeneic BMT, the occurrence of graft-versushost disease and the use of immunosuppressive therapy interfere in the T cell immune recovery, which results in a higher incidence of VZV reactivation [9] .
Peripheral blood progenitor cell transplantation (PBPCT), a procedure increasingly used to treat patients with hematologic malignancies and solid tumors, results in a more rapid hematopoietic recovery than does BMT. The data on immune reconstitution in this setting are limited and controversial, however, because it is not well established whether there is a more rapid immune recovery among patients who undergo PBPCT than among those who undergo BMT [10] [11] [12] [13] [14] . The few reports concerning VZV infections in patients who have undergone autologous PBPCT report an incidence of 6%-18.6%, which is lower than that reported among patients who undergo autologous BMT [15] [16] [17] . Despite the use of acyclovir [18] [19] [20] or immunization with VZV vaccine [21] in patients undergoing BMT, so far data regarding the effectiveness of the prophylaxis and its duration are limited and controversial; moreover, no data are available concerning patients for whom this approach should be reserved, particularly among autologous transplant recipients. The aim of the present study was to identify the patients who need prophylaxis for VZV infections by developing a risk model. 
PATIENTS, MATERIALS, AND METHODS

Patient characteristics.
We retrospectively reviewed VZV infections that occurred after autologous PBPCT in 164 adult patients (median age, 47 years [range, 16-68 years] ). The clinical characteristics of the study population are summarized in table 1. One hundred thirty-six patients had lymphoid malignancies: 77 had non-Hodgkin's lymphoma, 19 had Hodgkin's disease, 35 had multiple myeloma, and 5 had acute lymphoblastic leukemia. Sixteen patients had solid tumors, and 12 patients had myeloid malignancies: 9 had acute myeloid leukemia, and 3 had chronic myeloid leukemia. Before they underwent PBPCT, 51 patients (31%) were in complete remission, 93 (57%) were in partial remission, and 20 (12%) had progressive disease. All patients showed a good performance status, although 79 patients (48.2%) received 12 different chemotherapy regimens, and 85 patients (51.8%) received 110 previous chemotherapy courses. Conditioning regimens were chosen according to the underlying disease: lymphoproliferative disorders were treated with high-dose melphalan alone (in 18 [13. 4%] of patients) or in combination with other drugs (BEAM [carmustine, etoposide, aracytin, and melphalan], thiotepa, busulfan, or mitoxantrone, in 77 [56.7%]); total body irradiation and chemotherapy were administered to only 14 patients (8.5%). All but 2 patients (7.3%) with leukemia were treated with busulfan-cyclophosphamide, and all patients but 1 (6.1%) with solid tumors were treated with ifosfamide, carboplatin, and etoposide. Other conditioning regimens were used occasionally.
Patient care and follow-up. During the period of granulocytopenia, patients were housed in a positive-pressure highefficiency particulate air-filtered room and received antimicrobial prophylaxis with ciprofloxacin ( mg/day, given 2 ϫ 500 orally), fluconazole (200-400 mg/day, given orally), or itraconazole (300 mg/day). All patients received iv acyclovir (15 mg/kg/day) from the day of transplantation (day 0) to discharge; then they continued with acyclovir (15 mg/kg/day, given orally) until day ϩ30. From day ϩ15 to day ϩ30, patients received trimethoprim-sulfamethoxazole (2 tablets/day twice per week). Empirical antibiotic therapy was started when the body temperature was 138.3ЊC.
On days 0 and ϩ1, patients received a median of cells/ 6 6 ϫ 10 kg of CD34 ϩ cells (range, 0.51-cells/kg), mobilized 6 61.3 ϫ 10 and collected as described elsewhere [16] . All patients received granulocyte colony-stimulating factor (5 mg/kg/day) starting 5 days after PBPC reinfusion until the WBC count reached 5000 cells/mL. Irradiated blood products were infused to maintain hemoglobin and platelet levels 18 g/dL and 10,000 platelets/mL, respectively.
After discharge, a case history, physical examination, blood cell counts, and biochemical evaluation were done, and bone marrow aspirate and biopsy specimens were collected for all patients at day 30, 60, and 90 and then every 3 months only for patients with marrow involvement of the disease. For monitoring tumor mass status, CT scan was done within 3 months after transplantation and then every 6 months or when appropriate.
Flow cytometric enumeration of lymphocyte subpopulations and determination of serum immunoglobulin levels. At 1, Figure 1 . Actuarial probability of varicella-zoster virus (VZV) infection in 164 recipients of peripheral blood progenitor cell transplantation (10%, 17%, and 24% at 1, 2, and 3 years, respectively). 3, 6, 9, and 12 months, a flow cytometric analysis of the lymphocyte subpopulations (absolute lymphocyte count,
and the CD4:CD8 cell ratio) was done. Briefly, 100 mL of whole blood anticoagulated with EDTA was incubated for 30 min at 4ЊC with appropriate amounts of fluorescein isothiocyanateor phycoerythrin-conjugated monoclonal antibodies; CD3 ϩ and CD4 ϩ monoclonal antibodies were purchased from Immune Source, and all others were purchased from Becton Dickinson. Afterwards, RBCs were lysed by adding NH 4 Cl for 10 min. For flow cytometric analysis, gated lymphocyte population forward scatter versus side scatter was analyzed with a Becton Dickinson FACScan flow cytometer, and у10 4 events in this gate were analyzed. Serum immunoglobulin levels were determined at day ϩ30 after transplantation by use of a Behring nephelometer system BNA II (Dade Behring).
Definitions. Herpes zoster was defined as the appearance of typical vesicular skin lesions with a dermatomal distribution. Disseminated herpes zoster consisted of 6 skin lesions beyond the boundaries of the primary dermatome and/or visceral involvement.
We do not know pretransplantation VZV serological results for our patients; therefore, we cannot distinguish between primary infection (varicella) or reactivation (herpes zoster). We defined varicella as vesicular eruption with a generalized onset and no dermatomal distribution, irrespective of previous VZV infection, according to Schuchter et al. [7] . Postherpetic neuralgia was defined as dermatomal pain that persisted for 128 days after the onset of infection [7] .
Normal ranges of lymphocytes for our laboratory are as follows: total lymphocytes, 1700-2300 cells/mL; CD19 [3] . Study design and statistical methods. From June 1991 through December 1998, 164 patients underwent PBPCT at our institution. Charts of these patients were examined retrospectively by some authors and were reviewed by 3 physicians who are specialists in the study subject. Definitions and end points of the study were constructed before examination of the charts. Data were analyzed by means of descriptive statistical methods, and differences among groups were calculated by means of the x 2 test or Fisher's exact test as appropriate. Factors that affected development of infection were investigated by use of logistic stepwise analysis; the variables were selected by a stepwise backward method and were excluded from the model when the probability was 10 We constructed a risk model for VZV infection, scoring the parameters that were significant at the multivariate analysis. This scoring system includes CD8 ϩ T cell count (у800 cells/ mL, 0; !800 cells/mL, 1) and CD4 ϩ T cell count (у200 cells/ mL, 0; !200 cells/mL, 1). Afterwards, the patients were stratified into the following 3 groups: low-risk, score of 0 (i.e., CD8 ϩ T cells у800 cells/mL, and CD4 ϩ T cells у200 cells/mL); intermediate-risk, score of 1 (i.e., CD8 ϩ T cells !800 cells/mL or CD4 ϩ T cells !200 cells/mL); high-risk, score of 2 (i.e., CD8 ϩ T cells !800 cells/mL and CD4 ϩ T cells !200 cells/mL). These groups were included in a proportional hazards model [22] to evaluate whether the aforementioned factors were discriminant regarding the risk of VZV reactivation. The probability of events were obtained by use of the KaplanMeier method [23] , and the groups were compared by means of the log rank test [24] . Significance was established at P ! Figure 3 . Probability of achieving a CD4 ϩ cell count of 1400 cells/ mL after undergoing peripheral blood progenitor cell transplantation (15%, 38%, and 69% and month 3, 6, and 12, respectively).
Figure 4. Probability of achieving a CD4
ϩ cell count of 1400 cells/ mL after undergoing peripheral blood progenitor cell transplantation in patients with and without varicella-zoster virus (VZV) infection. Probability was significantly lower in patients with VZV infection ( ). P ! .02 (2-sided). Data were analyzed by use of the SPSS statistical .05 package (SPSS).
RESULTS
Patients' follow-up and outcome. We observed 164 patients for a median follow-up of 28.8 months (range, 1.4-98.2 months); 117 patients (71.3%) had a follow-up of у12 months.
Sixty-six patients (40.2%) died, and the median time of survival was 34.7 months. Seventy-eight patients (47.6%) had a relapse or progression, but 70% of patients were alive and free from disease progression at month 12 of follow-up. Hematopoietic recovery and early infection in this study population have been described elsewhere [16] .
VZV infection. Twenty-six patients (15.8%) developed VZV infection after they underwent PBPCT; the median time until onset was 7 months (range, 1.6-35.6 months), and 65.4% and 77% of the cases occurred during the first 12 and 24 months, respectively. The actuarial risk of VZV infection was 10% and 17% at 1 and 2 years, respectively, with a plateau after 3 years (figure 1).
Twenty-four infections (92.3%) occurred in patients with lymphoproliferative disorders. The characteristics of VZV infections are shown in table 2.
Twenty-four patients (92.3%) developed dermatomal herpes zoster, whereas only 1 patient (3.8%) had cutaneous dissemination, and 1 patient presented with varicella. We did not observe any visceral disseminations, and no death was related to VZV infection. The dermatomal distribution of VZV infection is shown in table 2. All patients with dermatomal VZV received acyclovir (800 mg 5 times per day, given orally) for 7-10 days, or more, if appropriate, whereas patients with disseminated VZV or varicella were treated with acyclovir (10 mg/kg 3 times per day, given iv) for 1 week, followed by 800 mg 5 times per day, given orally, for 7-10 days, or more if appropriate. Postherpetic neuralgia occurred in 8 patients (32%), and this complication required analgesic therapy for a median of 3 months (range, 1-18 months).
Immune recovery. The mean total lymphocyte count stayed within the normal range through the posttransplantation period, although 11 patients (12.4%) had lymphocyte counts below the normal range during the 3-month period after they underwent PBPCT. CD3 ϩ cells showed a pattern of recovery similar to total lymphocytes (figure 2). The mean number of CD8 ϩ cells reached the normal ref-
erence range at 1 month, increased during month 3, and dropped 6 months after transplantation, remaining within the normal range for the 12-month period (figure 2). However, the CD8 ϩ cell count was below the normal range in one-third of patients through the follow-up, excluding month 3; moreover, the number of CD8 ϩ cells remained below 800 cells/mL in almost half the patients during the 12-month period (except for month 3; table 3).
On the other hand, the mean CD4 ϩ cell count was far below the normal range during the 12-month period, although it showed a slow but progressive increase (figure 2). The probability of reaching a CD4 ϩ cell count of 1400 cells/mL was 15% at 3 months, 38% at 6 months, and 69% at 12 months ( figure  3 ). This probability was significantly lower in patients with VZV reactivation than in patients without VZV reactivation (figure 4). The proportions of patients with normal CD4 ϩ cell counts and with CD4 ϩ cell counts !200 cells/mL during follow-up are shown in table 3. Consequently, the CD4:CD8 ϩ cell ratio was less than half the normal value during the observation period (figure 2). With regard to B lymphocyte recovery, we monitored the number of CD19 ϩ cells; they showed a progressive increase, reaching a normal mean count around month 9 (figure 2). The CD16 ϩ cell count remained slightly below the normal range, although it showed a slow trend to increase through the observation period (figure 2). Factors affecting VZV. Univariate analysis showed that 12 previous chemotherapy regimens ( ), a CD8 ϩ cell P p .01951 count of !800 cells cells/mL ( ), and a CD4 ϩ cell P p .00003 count of !200 cells/mL ( ) at day 30 after transplan-P ! .00001 tation were associated with VZV infection, whereas age, sex, performance status, conditioning regimen, previous chemotherapy courses, cumulative steroid dose, hypogammaglobulinemia, CD34 ϩ cell dose, total lymphocytes, CD3 ϩ cell count, CD4:CD8 cell ratio, CD16 ϩ cell count, and CD19 ϩ cell count were not (table 4) . Multivariate logistic regression analysis selected CD8 ϩ cell counts of !800 cells/mL (OR, 2.0; 95% CI, 1.5-2.5; ) and CD4 ϩ cell counts of !200 cells/mL (OR, P p .0073 2.8; 95% CI, 2.3-3.3;
) as factors associated with an P ! .0001 increased risk of VZV infection. When these 2 variables were combined and included in the multivariate analysis, they remained significant ( ; OR, 7.6; 95% CI, 6.6-8.6) at P p .0001 the expense of both single variables (table 5) . Therefore, adding 1 point for each of the 2 variables, we built up a numerical scoring system able to separate the study population into 3 subgroups: low-risk patients, intermediate-risk patients, and high-risk patients, with frequencies of VZV infection of 2.3%, 20%, and 50%, respectively. The actuarial risk of VZV infection at 1 year was 0, 16%, and 48%, respectively (figure 5). Moreover, in the high-risk group, most events happened during the first 12 months ( 
DISCUSSION
VZV remains latent in the sensory ganglia and reactivates with an annual incidence variable with aging; the reactivation occurs in ∼7 cases per 1000 among immunocompetent persons !70 years old and in 110 cases per 1000 among those 170 years old [25] . In patients undergoing allogeneic BMT, the incidence of VZV infection is far higher, at 150 cases per 1000 [5, 26] ; in patients undergoing autologous BMT, the annual incidence of VZV infection is lower but is still 140 cases per 1000 [7, 8] .
We reported an annual incidence of VZV infection of 21 cases per 1000 among patients who underwent PBPCT. Although this incidence is almost half that reported among patients who have undergone BMT, it is 3 times higher than that reported in healthy people !70 years old.
Several definitions for postherpetic neuralgia have been proposed [27] ; for this reason, it is difficult to compare the incidences reported by the different authors. We used the more common definition, allowing a comparison between our study and others concerning patients undergoing BMT [2, 7, 15, 28] . Our rate of incidence of postherpetic neuralgia (32%) is higher than those reported by the aforementioned authors (15%-32%). However, the rate of postherpetic neuralgia reported in our and in other studies [2, 7, 15, 28] is high enough to assert that oral acyclovir is not quite effective in the prevention of this complication in patients undergoing PBPCT. Famciclovir has been reported to significantly reduce the duration of postherpetic neuralgia in the immunocompetent host, compared with administration of acyclovir [29] . It would also be appropriate to investigate the efficacy of this and other drugs [30] in patients who have undergone PBPCT.
In our series, the overall frequency of VZV infection was 15.8%, which is similar to that (18.6%) reported by Bilgrami et al. [15] ; nevertheless, in their study population, more than half the patients had solid tumors, whereas, in our series, only 10% of patients had solid tumors. Considering that lymphoproliferative disorders were identified as the only significant risk factor for the development of infection [7] , it is curious that the frequency of VZV infection reported by Bilgrami et al. is higher than that we reported. We found that the actuarial risk of VZV was 10% at 1 year, in contrast with 25% and 30% reported by Schuchter et al. [7] and Locksley et al. [2] among patients who had undergone autologous and allogeneic BMT, respectively. Therefore, although, among patients who undergo PBPCT, the annual incidence, the frequency, actuarial risk, and severity of complications of VZV infection are lower than among patients who undergo BMT [5, 26] , they seem to be greater than those in healthy people and seem to be associated with considerable morbidity.
The pathogenesis of VZV reactivation has not been completely highlighted yet. Studies in rat [31] [32] [33] and human dorsal root ganglia [34] [35] [36] [37] have showed that the cell-mediated immunity limits virus reactivation by recognizing the IE63 protein, expressed during latency. Both CD4 ϩ and CD8 ϩ cells would be able to recognize this protein [38] , although during latency IE63 accumulates in the cytoplasm of infected neurons not expressing class I and II major histocompatibility complex antigens. The humoral immunity seems to play a marginal role in the prevention of VZV reactivation [39, 40] , although a recent study demonstrates that low serum levels of immunoglobulin were correlated with the frequency of herpesvirus infections after treatment with nucleoside analogues [41] . Clinical trials among immunocompromised patients found no significant association between T cell levels and VZV reactivation [3, 41, 42] . Some authors [43, 44] described this association in AIDS patients; in particular, Gershon et al. [44] demonstrated a strict association between the level of CD4 ϩ cells at the onset of varicella and the risk of subsequent herpes zoster in children with HIV infection. Others observed that factors affecting immune recovery, such as radiation conditioning [28] or chronic graft-versus-host disease [2, 6] , were significantly correlated with higher rates of VZV infection after transplantation.
In our series, we showed that CD4 ϩ or CD8 ϩ cell deficiencies at day 30 after PBPCT significantly increase the risk of VZV infection, whereas deficiencies in other lymphocyte subsets did not; moreover, patients with VZV showed a significant delay in recovery of CD4 ϩ lymphocytes, compared with patients without VZV. Therefore, our data suggest that, in immunocompromised patients, VZV reactivation is limited by cell-mediated immunity and that both CD4 ϩ and CD8 ϩ cells participate in the cytotoxic response. We could separate the patients into 3 risk groups on the basis of their CD4 ϩ and CD8 ϩ lymphocyte counts: patients with CD4 ϩ cell counts !200 cells/mL and CD8 ϩ cell counts !800 cells/mL at day 30 after transplantation had an actuarial risk of VZV reactivation (50%) comparable to that of patients who underwent related-donor allogeneic BMT (51%), whereas patients without risk factors showed a negligible actuarial risk of infection. Regarding the patients with only 1 of the above risk factors, the actuarial risk at 1 year was 16%, which is nearer to that of healthy elderly people than to that of patients undergoing BMT. Despite the need of a prospective and definitive study, our data indicate that patients with lymphoid malignancies under-going PBPCT do not have a homogeneous risk of VZV reactivation; patients with CD4
ϩ and CD8 ϩ cell deficiencies (∼20%)
are at high risk of VZV infection and should be considered for a more prolonged chemoprophylaxis until more effective vaccines are available. Because the drugs now available are expensive and with significant toxicity, it should be useful to study prospectively the immune recovery to recognize if the loss of risk factors eventually allows for the interruption of chemoprophylaxis. Moreover, the recognized high-and intermediaterisk groups of patients could be the most suitable for investigating the effectiveness of currently available vaccines. Finally, further in vitro and in vivo studies are needed to clarify the pathogenesis of VZV reactivation in immunocompromised patients to devise more effective preventive strategies in the prevention of VZV infection among high-risk patients who undergo PBPCT.
